Neurologix announces positive results of gene therapy clinical trial in Parkinson...( Neurologix's Phase I trial showed posit...)

Neurologix's Phase I trial showed positive interim results in patients with Parkinson's disease. One year following treatment, patients exhibited a statistically significant improvement in motor function on the side of their body correlating to the treated part of the brain. Further, PET scans at one year revealed that the treated side of the brain exhibited a statistically significant decrease in abnormal metabolism, results considered similar to those achieved with STN Deep Brain Stimulation.

FORT LEE, N.J., Sept. 26, 2005 -- Neurologix, Inc. (OTCBB:NRGX) today announced positive interim results of its landmark gene therapy clinical trial for patients with Parkinson's disease. Neurologix's 12-patient, dose-escalating Phase I trial is the world's first study to use a viral vector (the non-pathogenic adeno-associated virus, or AAV) for the treatment of an adult neurological disease. In the Neurologix-funded trial, the vector was injected into a specific target site in the brain in order to transfer a gene to treat Parkinson's disease. The gene encodes glutamic acid decarboxylase (GAD), an enzyme which synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA).

Under the FDA-sanctioned trial protocol, patients with advanced Parkinson's disease received unilateral (one side of the brain) infusion of AAV-GAD via a hair-thin catheter into the subthalamic nucleus (STN), a deep brain structure known to function abnormally in Parkinson's patients. According to the interim findings, Neurologix's STN AAV-GAD treatment appears to be safe and well-tolerated in advanced Parkinson's disease, with no evidence of adverse effects or immunologic reaction related to the study treatment. Furthermore, patients in the trial, at one year, exhibited a statistically significant improvement (27%, p = .04) in motor function on the side of their body correlating to the treated part of the brain, as measured by the Unified Parkinson
'"/>

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006
Burns McClellan
25-Sep-2005

Page: 1 2 3 4 5 6
Related biology news :

1. Successful one year gene therapy trial for Parkinsons disease announced by Neurologix
2. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
3. ESA announces 2007 award recipients
4. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
5. Conservation Leadership Program announces 2007 awardees
6. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
7. Revolutionary global environment fund announces $50M expansion
8. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
9. Cell Press announces new partnership with the American Society of Human Genetics
10. ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML
11. Minister Lunn announces $39.6M for next phase of mountain pine beetle response